| Note |
Antidepressant therapy that causes insomnia can prevent a patient from flourishing during the day. Zoloft delivers first-line SSRI antidepressant efficacy with little potential for agitation or sedation. Zoloft (sertraline HCl/Pfizer) offers patients an escape from the confines of depression, with little risk of agitation, insomnia or sedation to hinder their return to a fulfilling life. While relieving the symptoms of depression with efficacy comparable to imipramine and amitriptyline, Zoloft has virtually no detrimental effect on psychomotor and cognitive performance that can interfere with daytime functioning - and may result in non-compliance to therapy. Favourable safety profile. Tricyclics have a narrower therapeutic margin, particularly in the elderly, and may cause serious drug intoxication. In cases of overdose at up to 10 times the maximum recommended dose of Zoloft, all patients have made a complete recovery. Zoloft has few cardiac effects and is not associated with significant ECG abnormalities. Favourable pharmacokinetic profile. Zoloft has no intrinsic anticholinergic activity to cause the troubling side effects traditionally associated with antidepressant therapy. And Zoloft produces no clinically active metabolites, has a significantly shorter half-life than fluoxetine and a low risk of drug interaction. In fact, Zoloft can usually be prescribed for the elderly with no dosage adjustment. Zoloft. Effective liberation from depression with few side effects to compromise your patient's recovery. Zoloft once a day. Day or night. |
